Effects of estradiol on HIF-1α expression and trophoblast differentiation in first trimester villous explant cultures

Geum Joon Cho1,*, Lyn Hwa Lee2,*, Bona Lee1, Jaeun Lee1, Ki-Hoon Ahn1, Soon-Cheol Hong1, Hai-Joong Kim1, Min-Jeong Oh1

1Department of Obstetrics and Gynecology, Korea University College of Medicine; 2J & L Women’s Clinics, Seoul, Korea

Objective
The purpose of this study was to investigate the effects of estradiol on the expression of hypoxia-inducible factor (HIF)-1α and the differentiation of trophoblasts in human first trimester villous explant cultures.

Methods
Villous explant cultures were established from first trimester human placentas (6–8 weeks of gestation, n=3). Normal villous tissues were explanted on Matrigel and incubated under 3% O2 tension for 5 days. To evaluate the effects of estradiol on the villous explant cultures, 1 ng/mL of estradiol was added to the culture medium. The morphological integrities and viabilities of the villous explants were monitored. Immunohistochemistry for α5 and α1 integrin was performed to assess differentiation of extravillous trophoblasts (EVTs). Expression of HIF-1α in villous explant cultures was evaluated by western blotting and densitometry.

Results
EVTs emerging from first trimester villous explant cultures formed outgrowths of cells from the distal ends and invaded the surrounding Matrigel. Exposure of villous explants to estradiol resulted in the decreased outgrowth of cells from the distal end and decreased expression of α5 integrin. However, estradiol treatment increased the invasion of villous explants into the surrounding Matrigel, concomitant with the increased expression of α1 integrin, indicating differentiation of EVT into more invasive EVT. On western blots, the expression of HIF-1α decreased significantly after treatment with estradiol under 3% O2 tension.

Conclusion
Our findings suggest that estradiol may downregulate expression of HIF-1α in placenta, which in turn promote trophoblast differentiation into invasive phenotype.

Keywords: Estradiol; Hypoxia-inducible factor-1α; Trophoblasts

Introduction
Regulation of trophoblast differentiation is critical for maintaining the pregnancy. Abnormalities in placental formation due to shallow trophoblast invasion may underlie the etiology of certain complications associated with human pregnancy such as preeclampsia and fetal growth restriction [1]. Trophoblast invasion is accompanied by a reduction in proliferative capacity of the cells and requires the regulated expression of either proteinases or adhesion molecules [2]. Especially, α1 integrin promotes invasion in vitro, whereas α5 integrin inhibits
this process [3].

For the majority of the first trimester, the placenta develops in a hypoxic environment [4]. This hypoxic environment is important for the control of extravillous trophoblast (EVT) outgrowth as it maintains trophoblasts in a proliferative, non-invasive, and immature phenotype [2], and reduces the invasive capacity of trophoblasts and the expression of molecules associated with an invasive trophoblast phenotype such as α1 integrin [5,6]. Intervillous blood flow increases at around 10–12 weeks of gestation, resulting in exposure of trophoblasts to increased oxygen tension [7]. This increased oxygen tension promotes trophoblast differentiation toward the invasive pathway [2,8].

In recent years, hypoxia-inducible factor (HIF) has been identified as a transcription factor that controls certain target genes under low oxygen tensions [9–11]. By regulating target genes, this transcription factor plays a role in angiogenesis, erythropoiesis, glycolysis, vascular tone, pH homeostasis, and cell survival decisions like proliferation and apoptosis [7,10,12]. HIF is a heterodimer composed of an oxygen-regulated α-chain (HIF-1α or HIF-2α) and a β-subunit (HIF-β). In the presence of oxygen, 2 prolines of the HIF-1α chain are hydroxylated by prolyl hydroxylases with oxygen acting as the substrate. The hydroxylated prolyl residues are recognized by the von Hippel-Lindau protein as a component of the E3 ubiquitin ligase, which targets HIF-1α for proteasomal degradation. In contrast, under low oxygen tensions, HIF accumulates in the cell and induces transcription of target genes [10,11].

HIF-1α is known to inhibit trophoblast differentiation toward invasive EVTs [7]. HIF-1α is highly expressed in the placenta from early gestation (between 5–8 weeks) and then levels of this protein fall suddenly around gestational week 10–12 when intervillous blood flow and placental oxygenation begin to increase [13]. This decrease in the level of HIF-1α allows trophoblast differentiation into invasive EVTs that invade deep into the maternal uterus [7]. Abnormally elevated HIF-1α could result in the arrest of trophoblasts in a relatively immature state of differentiation, resulting in shallow trophoblast invasion into the uterus and reduced uteroplacental perfusion [7].

Estradiol is essential for the initiation and maintenance of pregnancy in humans as well as in experimental animals [14]. Maternal serum estradiol level begins to rise during weeks 6–8 of gestation when placental function becomes apparent. Estradiol can induce trophoblast differentiation [15,16]. Recent studies reported that estradiol downregulates the expression of HIF-1α both in vivo [17] and in vitro [18].

Taken together, these results led us to hypothesize that estradiol controls trophoblast differentiation by inhibiting HIF-1α. The purpose of this study was to investigate the effects of estradiol on the expression of HIF-1α and trophoblast differentiation in human first trimester placentas.

Materials and methods

1. Explant cultures

Villous explant cultures were established from first trimester human placentas of normal pregnancy (6–8 weeks of gestation, n=3). Gestational age was calculated from the date of the last menstrual period and, if necessary, was adjusted according to ultrasonic measurements of the gestational sac and fetal crown-rump length.

All subjects provided informed consent prior to participation in the study, and this study was approved by the Institutional Review Board of Korea University College of Medicine.

All villi were from concordant pregnancies. Small pieces of tissue (2–3 mm) from the periphery of the placental debris were dissected (usually 4–8 villus tips per sample). To prepare rat-tail collagen I-coated plates (BD Biosciences, Bedford, UK), 0.8 mL of collagen I (Invitrogen, Grand Island, NY, USA) was mixed with 0.1 mL of 10×DMEM (1:10; Invitrogen) and 0.1 mL of 7.5% NaHCO₃ (1:10). For each explant, 80 µL of collagen was placed in the center of a 12-well culture dish. Gels were prepared by placing a drop of the appropriate substrate in 12-well culture dishes. Matrigel (BD Biosciences) was aliquoted at 4°C and warmed to 37°C to gel. Gels were produced at least 24 hours before use and incubated in medium at 37°C to allow full contracture. After formation of the gels (30 minutes at 37°C), the dissected tissue pieces were carefully placed on top of each gel drop, were covered with 20 µL of medium, and incubated for 2–4 hours to allow for proper anchorage. Subsequently, explants were flooded with 1 mL of DMEM/F12 (Invitrogen) supplemented with 10% FBS (JR Scientific, Woodland, CA, USA) and incubated overnight at 37°C with 5% CO₂. Normal range of estradiol level is 0.55–5.10 ng/mL in 6–7 weeks of gestation, respectively [19]. We adapted 1 ng/mL as physiologic level in this study. After an initial period of 24 hours, during which cytotrophoblast proliferation occurred at the villous tips, 1 ng/mL of estradiol (1,3,5[10]-Estratriene-3,17-diol, cell-culture tested; Sigma, St.
Louis, MO, USA), 0.1 or 10 ng/mL of estradiol were added to the culture medium, and the explant cultures were then incubated for approximately 5 days. Control experiments were run in parallel using explants from the same placenta cultured in medium alone. Culture media were changed every 48 hours and collected. The viabilities of the explant cultures were assessed by measuring human chorionic gonadotropin levels.

2. Assessment of trophoblast outgrowth and invasion
EVT outgrowth occurred largely across the surface of the gel. Outgrowth and invasion were examined qualitatively taking into account the morphology of the constituent cells. Images were taken at different time points with a digital inverted microscope (Olympus IX71 and CKX41 camera; Olympus, Tokyo, Japan).

3. Western blotting
Protein lysates were obtained using a buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM MgCl₂, 1 mM EDTA, 10% glycerol, 1% Triton X-100, and a mixture of protease inhibitors (aprotinin, phenylmethylsulfonyl fluoride, and sodium orthovanadate). Total tissues lysates were prepared by homogenization. The extracted protein concentration was measured according to the method of Bradford. Equal amounts of total protein (10 µg/sample) were resolved on a 12% sodium dodecyl sulfate-polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were transferred to a nitrocellulose membrane (HybondTM-P; Amersham Biosciences, Piscataway, NJ, USA). After blocking with TBS and 0.1% Tween-20 at 4°C overnight, the membranes were incubated with primary antibodies for anti-mouse HIF-1α (dilution 1:1,000; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and anti-mouse glyceraldehyde 3-phosphate dehydrogenase (dilution 1:2,000; Bio-Rad Hercules) for 24 hours followed by incubation with secondary antibodies linked to horseradish peroxidase. Immunoreactive proteins were visualized by chemiluminescence using SuperSignal West Dura Extended Duration Substrate (Pierce Chemical Co., Rockford, IL, USA), and the signals were detected on X-ray film (Agfa-Gevaert, Mortsel, Belgium).

Signals in the linear range of the film were digitized, and densitometry was performed using IMT-i-Delta (Image and Microscope Technology, Daejeon, Korea).

4. Immunohistochemical staining for integrins
To confirm the differentiation of the trophoblasts into invasive EVTs, immunohistochemistry staining for α1 and α5 integrins was performed. Briefly, tissue sections (5 µm) were deparaffinized and then rehydrated and blocked with 3% H₂O₂ in methanol for 30 minutes followed by universal blocking (normal serum, 1.5%; Vector Laboratories, Burlingame, CA, USA). Antibodies reactive to mouse anti-human integrin α1 (Santa Cruz Biotechnology Inc.) or rabbit anti-human integrin α5 (Santa Cruz Biotechnology Inc.) were used at dilutions of 1:100 and were incubated with the samples for 1 hour. After the primary antibodies were applied, the slides were incubated overnight at room temperature. Detection was performed using a secondary antibody (Vector Laboratories). All samples were counterstained with Mayer’s hematoxylin before mounting with Immunomount (Lab Vision, Fremont, CA, USA).

5. Statistics
Three explants from a single placenta were evaluated for each treatment point. Results were analyzed using the Mann-Whitney U test. P<0.05 was considered statistically significant.

Results

1. Effects of estradiol on outgrowth and invasion of EVTs
Villous explants from gestational weeks 6 to 8 were maintained in culture for 5 days under 3% O₂ tension with 1 ng/mL of estradiol. Control experiments were run in parallel using explants from the same placenta cultured in medium alone. EVTs emerging from first trimester villous explant cultures formed outgrowths of cells from the distal end and invaded the surrounding Matrigel (Fig. 1). Exposure of villous explants to estradiol increased EVT invasion into the surrounding Matrigel (arrow, Fig. 1D) when compared to control villous explants, which showed the typical low O₂ tension-induced outgrowth (arrowhead, Fig. 1C).

2. Effects of estradiol on EVT differentiation
To confirm the differentiation of trophoblasts into invasive EVTs, we performed immunohistochemical staining for α1 and α5 integrins (Fig. 2). A few cells immunopositive for α5 integrin were noted in explants cultured with 1 ng/mL of estradiol under 3% O₂ tension. However, strong positive immunoreactivity for α1 integrin was observed in explants cultured with 1 ng/mL of estradiol when compared to control villous explants.
3. Effects of estradiol on the expression of HIF-1α in villous explant cultures

To determine whether estradiol plays a role in modulating the expression of HIF-1α, we studied the effect of estradiol on the expression of HIF-1α in villous explant cultures (Fig. 3). On western blots, the protein expression of HIF-1α was detected in both untreated villous explants under 3% O₂ tension and with 1 ng/mL of estradiol (physiologic level) under 3% O₂ tension. The expression of HIF-1α in villous explant cultures from gestational weeks 6 to 8 decreased significantly after treatment with 1 ng/mL of estradiol under 3% O₂ tension when compared to the control villous explants (Fig. 3A). Corresponding densitometric analysis confirmed these results (Fig. 3B).

4. Effects of different doses of estradiol on the expression of HIF-1α

Next, to investigate the expression of HIF-1α at different doses of estradiol, villous explants were cultured with 0.1 or 10 ng/mL of estradiol under 3% O₂ tension for 5 days, and the expression of HIF-1α was compared with that of control explant cultures (Fig. 4). The expression of HIF-1α from villous explants cultured with 1 ng/mL of estradiol was lower than that of untreated villous explants. However, the expression of HIF-1α from explant cultures treated with 0.1 or 10 ng/mL of estradiol was greater than that of control villous explants (Fig. 4A). Corresponding densitometric analysis confirmed these results (Fig. 4B).

Discussion

To the best of our knowledge, this study was the first to report that a physiologic level of estradiol downregulates the hypoxic induction of HIF-1α, and promotes trophoblast differentiation toward invasive EVTs in first trimester villous explant cultures. The HIF-1α protein is significantly overexpressed in preeclamptic placentas [20], and villous explants from preeclamptic placentas fail to adequately downregulate HIF-1α protein expression upon oxygenation [21], although the cause of aberrant HIF-1α expression in preeclamptic placentae remains to be elucidated. Estrogen is essential for the initiation and maintenance of pregnancy [14]. Especially, it has been known that estrogen influences placental growth and increases the fetoplacental blood flow [22,23]. The association of estradiol with preeclampsia has been also suggested.

Fig. 1. Effects of estradiol on extravillous trophoblast outgrowth and invasion in first trimester villous explant cultures. Dissected villous tissues were cultivated on Matrigel under 3% O₂ tension (A, C) or under 3% O₂ tension with 1 ng/mL of estradiol (B, D). A series of images were taken under an inverted microscope at ×10 magnification at day 0 (A, B) and day 5 (C, D).

Fig. 2. Immunolocalizations of α5 and α1 integrins in villous explants. Sections of explants cultured under 3% O₂ tension (A, C) or under 3% O₂ tension with 1 ng/mL of estradiol (B, D) were stained for α5 (A, B) or α1 integrin (C, D). Images were taken at ×40 magnification.
Geum Joon Cho, et al. Effects of estradiol on trophoblast

from several studies, although the mechanism underlying the association is still unclear. Several studies measuring estradiol in blood from preeclamptic women have reported lower estradiol levels [24-26] than in the controls, while others have not found a difference [27-29]. Moreover, some studies have reported a positive effect of estradiol administration on severe preeclampsia [30,31]. Reduced estrogen exposure has been hypothesized to explain the lower risk of breast cancer found in women with preeclamptic pregnancies [32] and in their daughters [33].

Our study suggests that inappropriate levels of estradiol could contribute to an elevation in the placental levels of HIF-1α, which could lead to the shadow invasion of trophoblasts into the spiral arteries and uterine wall, as seen in preeclampsia. Hypoxia and placental insufficiency may lead to a deficiency in placental estrogen, which in turn may result in further elevation of placental HIF-1α levels [27,34], resulting in a vicious cycle. Elevated levels of HIF-1α induced by inappropriate levels of estradiol may induce the transcription of target genes, such as soluble vascular endothelial growth factor receptor-1, which plays a major role in the pathogenesis of preeclampsia [35].

The molecular mechanisms by which estradiol regulates expression of HIF-1α in explant cultures have yet to be determined, but we propose the following hypotheses. First, the effects of estradiol on HIF-1α may be due to activation of one or both of the 2 estrogen receptors (ERs), ERα and ERβ. Estradiol attenuated the hypoxic induction of HIF-1α in Hep3B cells, but an ER antagonist eliminated these effects of estradiol, indicating that estradiol may downregulate HIF-1α through an ER-dependent mechanism [18]. It is known that homozygous T-A haplotype carriers of ERα PvuII and XbaI gene polymorphisms have an increased risk of severe preeclampsia [36], and a single nucleotide polymorphism of the ERβ gene was linked to preeclampsia after stratification according to the presence of a family history of hypertension [37]. These may be possible reasons why studies measuring the levels of estradiol in the
blood of preeclamptic women have reported conflicting results. Second, estradiol may control HIF-1α via 2-methoxyestradiol (2-ME). 2-ME is a natural metabolite of estradiol and possesses antitumor and antiangiogenic activity [38]. 2-ME has low affinities for ERα and ERβ, and its antiproliferative activity is independent of any interaction with these receptors [39]. 2-ME destabilizes microtubules and downregulates HIF-1α [40]. During pregnancy, 2-ME is generated by catechol-O-methyltransferase (COMT) in the placenta [41], and its maternal serum level increases during the third trimester of normal human pregnancy [42]. However, the placental activity of COMT is suppressed in women with preeclampsia [43], and the circulating level of 2-ME is lower in women with preeclampsia than in normal pregnant women [44]. It has been reported that pregnant mice deficient in COMT developed multiple functional and structural features consistent with a preeclampsia-like phenotype due to the absence of 2-ME [44]. Therefore, the estradiol-mediated attenuation of HIF-1α may be a function of the production of 2-ME by COMT in villous explant cultures. However, we did not evaluate ER status nor the expression levels of 2-ME or COMT in villous explant cultures. Therefore, further studies are required to better understand the molecular mechanisms by which estradiol regulates the expression of HIF-1α in pregnancy.

In this study, a physiologic level of estradiol (1 ng/mL) decreased the expression of HIF-1α, whereas 0.1 and 10 ng/mL of estradiol increased the expression of HIF-1α when compared to control villous explants. The mechanism underlying these results is unclear. Some studies have reported that estradiol downregulates the expression of HIF-1α [17, 18]. Conversely, others have reported that estradiol increases the expression of HIF-1α [45]. It seems likely that the effects of estradiol on HIF-1α may differ according to the concentration of estradiol employed.

HIF-1α is highly expressed in the placenta and maternal serum estradiol level begins to rise at around 5–8 weeks of gestation. However, as intervillous blood flow increases at around 10–12 weeks of gestation, levels of HIF-1α fall suddenly and trophoblast was differentiated toward invasive pathway [13]. This study was to investigate the effects of estradiol on expression of HIF-1α and differentiation of trophoblast. Therefore, to control these characteristics of placentas acquired at around 10–12 weeks of gestation, we used the placentas from 6 to 8 weeks gestations.

In conclusion, we suggest that physiologic levels of estradiol may downregulate expression of HIF-1α, which in turn promote trophoblast differentiation into invasive phenotype. This raises the possibility that inappropriate levels of estradiol might contribute to major complications of pregnancy that are associated with abnormal trophoblast invasion and placental development, such as preeclampsia. Further studies are needed to evaluate the role of estradiol on pathophysiology of preeclampsia and clinical effects of administration with estradiol on preeclamptic patients.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993;91:950-60.
2. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest 1996;97:540-50.
3. Damsky CH, Librach C, Lim KH, Fitzgerald ML, McMaster MT, Janatpour M, et al. Integrin switching regulates normal trophoblast invasion. Development 1994;120:3657-66.
4. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 1992;80:283-5.
5. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997;277:1669-72.
6. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta 2000;21 Suppl A:S25-30.
7. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest
Geum Joon Cho, et al. Effects of estradiol on trophoblast
2000;105:577-87.
8. Zhou Y, Genbacev O, Damsky CH, Fisher SJ. Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. J Reprod Immunol 1998;39:197-213.
9. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004;19:176-82.
10. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
11. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
12. Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther 2004;3:29-35.
13. Rajakumar A, Conrad KP. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. Biol Reprod 2000;63:559-69.
14. Matsuura S, Itakura A, Ohno Y, Nakashima Y, Murata Y, Takeuchi M, et al. Effects of estradiol administration on feto-placental growth in rat. Early Hum Dev 2004;77:47-56.
15. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev 1995;16:608-48.
16. Cronier L, Guibourdenche J, Niger C, Malassiné A. Oestradiol stimulates morphological and functional differentiation of human villous cytotrophoblast. Placenta 1999;20:669-76.
17. Nickel EA, Hsieh CH, Chen JG, Schwacha MG, Chaudry IH. Estrogen suppresses cardiac IL-6 after trauma-hemorrhage via a hypoxia-inducible factor 1 alpha-mediated pathway. Shock 2009;31:354-8.
18. Mukundan H, Kanagy NL, Resta TC. 17-beta estradiol attenuates hypoxic induction of HIF-1alpha and erythropoietin in Hep3B cells. J Cardiovasc Pharmacol 2004;44:93-100.
19. Dawood MY, Ratnam SS. Serum unconjugated estradiol-17 beta in normal pregnancy measured by radioimmunoassay. Obstet Gynecol 1974;44:194-9.
20. Rajakumar A, Whitelock KA, Weissfeld LA, Daftary AR, Markovic N, Conrad KP. Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with pre eclampsia. Biol Reprod 2001;64:499-506.
21. Rajakumar A, Doty K, Daftary A, Harger G, Conrad KP. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placenta. Placenta 2003;24:199-208.
22. Abdul-Karim RW, Nesbitt RE Jr, Drucker MH, Rizk PT. The regulatory effect of estrogens on fetal growth. I. Placental and fetal body weights. Am J Obstet Gynecol 1971;109:656-61.
23. Storment JM, Meyer M, Osol G. Estrogen augments the vasodilatory effects of vascular endothelial growth factor in the uterine circulation of the rat. Am J Obstet Gynecol 2000;183:449-53.
24. Ranta T, Stenman UH, Unnérus HA, Rossi J, Seppälä M. Maternal plasma prolactin levels in preeclampsia. Obstet Gynecol 1980;55:428-30.
25. Allen EI, Lachelin GC. A comparison of plasma levels of progesterone, oestradiol, unconjugated oestriol and total oestriol with urinary total oestrogen levels in clinical obstetric practice. Br J Obstet Gynaecol 1978;85:278-92.
26. Walsh SW. Progesterone and estradiol production by normal and preeclamptic placentas. Obstet Gynecol 1988;71:222-6.
27. Rosing U, Carlström K. Serum levels of unconjugated and total oestrogens and dehydroepiandrosterone, progesterone and urinary oestriol excretion in pre-eclampsia. Gynecol Obstet Invest 1984;18:199-205.
28. Acromite MT, Mantzoros CS, Leach RE, Hurwitz J, Dorey LG. Androgens in preeclampsia. Am J Obstet Gynecol 1999;180:60-3.
29. Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D, et al. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. Int J Epidemiol 2003;32:455-60.
30. Smith GV, Smith OW. Estrogen and progesterone metabolism in pregnancy. III. The effect of hormone administration in pre-eclampsia. J Clin Endocrinol 1941;1:477-84.
31. Mizutani S, Kurauchi O, Ito Y, Narita O, Tomoda Y. Positive effect of estradiol and progesterone in severe pre-eclampsia. Exp Clin Endocrinol 1988;92:161-70.
32. Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 2002;87:971-3.
Evidence of prenatal influences on breast cancer risk. Lancet 1992;340:1015-8.
34. Takanashi K, Honma T, Kashiwagi T, Honjo H, Yoshizawa I. Detection and measurement of urinary 2-hydroxyestradiol 17-sulfate, a potential placental antioxidant during pregnancy. Clin Chem 2000;46:373-8.
35. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291:R1085-93.
36. Molvarec A, Vér A, Fekete A, Rosta K, Derzbach L, Derzszy Z, et al. Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res 2007;30:205-11.
37. Maruyama A, Nakayama T, Sato N, Mizutani Y, Furuya K, Yamamoto T. Association study using single nucleotide polymorphisms in the estrogen receptor beta (ESR2) gene for preeclampsia. Hypertens Res 2004;27:903-9.
38. Pribluda VS, Gubish ER Jr, LaVallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000;19:173-9.
39. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002;62:3691-7.
40. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
41. Casey ML, MacDonald PC. Characterization of catechol-O-methyltransferase activity in human uterine decidua vera tissue. Am J Obstet Gynecol 1983;145:453-7.
42. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh) 1983;103:282-8.
43. Barnea ER, Maclusky NJ, DeCherney AH, Naftolin F. Catechol-o-methyl transferase activity in the human term placenta. Am J Perinatol 1988;5:121-7.
44. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature 2008;453:1117-21.
45. Yun SP, Lee MY, Ryu JM, Song CH, Han HJ. Role of HIF-1alpha and VEGF in human mesenchymal stem cell proliferation by 17beta-estradiol: involvement of PKC, PI3K/Akt, and MAPKs. Am J Physiol Cell Physiol 2009;296:C317-26.